Physician profile
Julia A Bowlin
NPI 1295787067
$565.58
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $30.49 · 2021: $290 · 2022: $27.59 · 2023: $37.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $90.84 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $82.97 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.44 | 2019-2021 | |
| Novo Nordisk INC | $59.10 | 2019-2021 | |
| Glaxosmithkline, LLC. | $50.40 | 2022-2023 | Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $41.76 | 2021 | |
| Novartis Pharmaceuticals Corporation | $29.37 | 2019-2020 | |
| Sanofi Pasteur INC. | $27.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.41 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.76 | 2021 | |
| Lilly USA, LLC | $14.47 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.84 | 2021 | |
| Daiichi Sankyo INC. | $13.32 | 2021 | |
| Abbvie INC. | $11.90 | 2021 | |
| Amarin Pharma, INC. | $11.48 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Bowlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.